About Interius Biotherapeutics
Interius Biotherapeutics is a company based in Philadelphia (United States) founded in 2020 was acquired by Kite Pharma in August 2025. Interius Biotherapeutics has raised $129.03 million across 4 funding rounds from investors including Pfizer, BrightEdge and Kite Pharma. The company has 25 employees as of December 31, 2021. Interius Biotherapeutics offers products and services including LENTIVECTOR Platform, INT2104, and INT2106. Interius Biotherapeutics operates in a competitive market with competitors including Moderna, Senti Biosciences, Horizon Therapeutics, Forge Biologics and argenx, among others.
- Headquarter Philadelphia, United States
- Employees 25 as on 31 Dec, 2021
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Interius Biotherapeutics, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$129.03 M (USD)
in 4 rounds
-
Latest Funding Round
$51.43 M (USD), Series A
May 21, 2024
-
Investors
Pfizer
& 16 more
-
Employee Count
25
as on Dec 31, 2021
-
Acquired by
Kite Pharma
(Aug 22, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Interius Biotherapeutics
Interius Biotherapeutics offers a comprehensive portfolio of products and services, including LENTIVECTOR Platform, INT2104, and INT2106.
System for precise delivery of genetic medicines to treat diseases.
Lentivector-based treatment targeting oncology applications.
Advanced therapeutic for autoimmunity via genetic medicine.
People of Interius Biotherapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of Interius Biotherapeutics
Interius Biotherapeutics has successfully raised a total of $129.03M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $51.43 million completed in May 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Interius Biotherapeutics
Interius Biotherapeutics has secured backing from 17 investors, including institutional and venture fund investors. Prominent investors backing the company include Pfizer, BrightEdge and Kite Pharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early- to growth-stage startups are targeted for venture capital investments.
|
Locked | Locked | Locked | |
|
Venture capital is directed toward healthcare companies by Longwood Fund.
|
Locked | Locked | Locked | |
|
Private equity fund focused on the biotechnology sector
|
Locked | Locked | Locked |
Investor details for Interius Biotherapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Interius Biotherapeutics
Investment portfolio details for Interius Biotherapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Interius Biotherapeutics
Detailed financials for Interius Biotherapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Interius Biotherapeutics Comparisons
Peer comparison for Interius Biotherapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Interius Biotherapeutics
Interius Biotherapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Senti Biosciences, Horizon Therapeutics, Forge Biologics and argenx, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Cell-based therapies for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Developer of drugs for treating rare and autoimmune diseases
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases are developed to treat patients.
|
|
| Locked | Locked | Locked |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment.
|
|
| Locked | Locked | Locked |
Genetically engineered cell therapies are developed for multiple disorders.
|
Detailed competitors of Interius Biotherapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Interius Biotherapeutics
Complete news archive for Interius Biotherapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Interius Biotherapeutics
Interius Biotherapeutics was founded in 2020.
Interius Biotherapeutics is headquartered in Philadelphia, United States. It is registered at Philadelphia, Pennsylvania, United States.
Interius Biotherapeutics is a funded company, having raised a total of $129.03M across 4 funding rounds to date.
As of Dec 31, 2021, the latest employee count at Interius Biotherapeutics is 25.
Interius Biotherapeutics was founded in 2020 in Philadelphia, United States, within the biotherapeutics sector. Gene therapies targeting various diseases are developed through lentiviral pseudotyping to improve efficiency. In-vivo generation of therapeutic cells, such as CAR-T cells for cancers, regulatory T cells for autoimmune conditions, and CD34 hematopoietic stem cells for blood disorders, is focused on by the company. Operations emphasize innovative cell transformation methods.
Interius Biotherapeutics's top competitors include Moderna, argenx and Forge Biologics.
Interius Biotherapeutics offers LENTIVECTOR Platform, INT2104, and INT2106.
Interius Biotherapeutics has 17 investors. Key investors include Pfizer, BrightEdge, Kite Pharma, Penn Medicine, and RA Capital.